Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

DOI: 10.1007/s00259-017-3670-z
European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024.

#	Paper	IF	Citations
524	Impact of Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. **2017**, 58, 1956-1961		90
523	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 1622-1635	8.8	59
522	Therapy assessment in prostate cancer using choline and PSMA PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 78-83	8.8	25
521	Non-invasive molecular imaging and theranostic probes. **2017**, 130, 1-3		1
520	Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga-Prostate-Specific Membrane Antigen PET/CT. **2017**, 42, 717-718		4
519	68Ga-PSMA Uptake in an Incidentally Detected Gastrointestinal Stromal Tumor in a Case of Suspected Carcinoma Prostate. **2017**, 42, e447-e448		11
518	Clinical PET Imaging in Prostate Cancer. **2017**, 37, 1512-1536		69
517	A rare case of thymoma first detected on gallium-68 PSMA PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 2148-2149	8.8	6
516	Reduction of Ga-PSMA renal uptake with mannitol infusion: preliminary results. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 2189-2194	8.8	20
515	PSMA Ligands for PET Imaging of Prostate Cancer. **2017**, 58, 1545-1552		120
514	[PET-CT and PET-MRI of the prostate : From F-FDG to Ga-PSMA]. **2017**, 57, 631-636		6
513	Procedures for the GMP-Compliant Production and Quality Control of [F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. **2017**, 10,		55
512	Optimal MRI sequences for Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. **2017**, 7, 77		27
511	Effects of Fasting on F-DCFPyL Uptake in Prostate Cancer Lesions and Tissues with Known High Physiologic Uptake. **2018**, 59, 1081-1084		8
510	Evolution of Nuclear Medicine in the diagnosis and treatment of prostate cancer. **2018**, 37, 71-72		
509	Advances in prostate-specific membrane antigen PET of prostate cancer. **2018**, 30, 189-196		17
508	Theranostic radiopharmaceuticals: established agents in current use. **2018**, 91, 20170969		48

507	Optimal time-point for Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1188-1196	8.8	25
506	Incidental Detection of Basaloid Thymic Carcinoma With Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. **2018**, 16, e497-e499		2
505	The impact of a Bayesian penalized-likelihood reconstruction algorithm on delayed-time-point Ga-68-PSMA PET for improved recurrent prostate cancer detection. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1461-1462	8.8	3
504	Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. **2018**, 123, 719-725		17
503	Potential Impact of Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. **2018**, 59, 1714-1721		64
502	Valor de las imgenes de 177 Lu-PSMA post-terapia para una interpretacin precisa de la respuesta a la terapia con PET/TC con 68 Ga-PSMA. **2018**, 37, 114-117		
501	Rare Case of Intratracheal Metastasis Detected on 68Ga-Prostate-Specific Membrane Antigen PET/CT Scan in a Case of Thyroglobulin Elevated Negative Iodine Scan Syndrome. **2018**, 43, 282-283		6
500	A review discussing fluciclovine (F) PET/CT imaging in the detection of recurrent prostate cancer. **2018**, 14, 1101-1115		7
499	Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands. **2018**, 36, 603-608		23
498	Prostate-specific membrane antigen theranostics: therapy with lutetium-177. **2018**, 28, 197-204		22
497	Current status of theranostics in prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 471-495	8.8	80
496	Comparison of Ga-PSMA-11 and F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. **2018**, 59, 789-794		54
495	Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. **2018**, 91, 153-163		62
494	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. **2018**, 38, 200-217		152
493	68 Ga-PSMA PET/CT in prostate cancer. **2018**, 37, 130-138		1
492	Will 68Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update. **2018**, 37, 103-109		
491	Will Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update. **2018**, 37, 103-109		2
490	Evolution of nuclear medicine in the diagnosis and treatment of prostate cancer. **2018**, 37, 71-72		

489	Synthesis of Realistic Simultaneous Positron Emission Tomography and Magnetic Resonance Imaging Data. **2018**, 37, 703-711		10
488	Impact of Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. **2018**, 59, 89-92		54
487	Prospective Evaluation of Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging. **2018**, 59, 803-808		46
486	Ga-PSMA PET/CT in prostate cancer. **2018**, 37, 130-138		5
485	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. **2018**, 59, 625-631		50
484	Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0. **2018**, 59, 479-485		81
483	The use of PET/CT in prostate cancer. **2018**, 21, 4-21		49
482	A New Type of Prostate Cancer Imaging: Will CuCl PET/CT Flourish or Vanish?. **2018**, 59, 442-443		5
481	PSMA PET: Transformational Change in Prostate Cancer Management?. **2018**, 59, 228-229		8
480	Impact of Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. **2018**, 59, 434-441		83
479	Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. **2018**, 78, 54-63		34
478	Prospective evaluation of F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 355-364	8.8	49
477	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. **2018**, 59, 469-478		202
476	Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. **2018**, 59, 230-237		164
475	Value of post-therapy Lu-PSMA images for accurate interpretation of therapy response with Ga-PSMA PET/CT. **2018**, 37, 114-117		
474	Gallium 68-PSMA PET/CT for lesion characterization in suspected cases of prostate carcinoma. **2018**, 39, 1013-1021		6
473	[PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection]. **2018**, 57, 69-73		2
472	Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. **2018**, 7, 831-843		22

471	Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction. **2018**, 17, 1536012118811741	4
470	Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy. **2018**, 43, e296-e303	12
469	Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology. **2018**, 43, e488-e491	8
468	Utility of 68Ga-PSMA-11 PET/CT in Imaging of Glioma-A Pilot Study. **2018**, 43, e304-e309	41
467	Impact of external cooling with icepacks on Ga-PSMA uptake in salivary glands. **2018**, 8, 56	37
466	Molecular Imaging in Oncology Using Positron Emission Tomography. **2018**, 115, 175-181	15
465	The Impact of a Bayesian Penalized-Likelihood Reconstruction Algorithm on a Dual-Time-Point Acquisition Protocol while Performing Ga-68-PSMA PET for Primary Prostate Cancer Detection. **2018**, 09,	
464	Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study. **2018**, 44, 892-899	14
463	68Ga-Radiopharmaka: Methode oder Episode?. **2018**, 41, 335-347	2
462	Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study. **2018**, 52, 420-429	20
461	Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer. **2018**, 128, 37-48	3
460	Importance of Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist. **2018**, 37, 302-314	5
459	Standardisation of PSMA images interpretation: why do we need it?. **2018**, 6, 331-333	4
458	Radioguided surgery with radiation: a novel application with Ga. **2018**, 8, 16171	13
457	Quantitative performance and optimal regularization parameter in block sequential regularized expectation maximization reconstructions in clinical Ga-PSMA PET/MR. **2018**, 8, 70	22
456	Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on F-DCFPyL PET/CT Imaging. **2018**, 59, 1857-1864	28
455	Diagnostic Accuracy of Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. **2018**, 289, 730-737	75
454	Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. **2018**, 19, 819-831	16

453	Oncology. **2018**, 257-308		
452	Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses. **2018**, 6, 223-237		2
451	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. **2018**, 211, 286-294		18
450	Reproducibility of standardized uptake values of same-day randomized Ga-PSMA-11 PET/CT and PET/MR scans in recurrent prostate cancer patients. **2018**, 32, 523-531		13
449	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 2045-2054	8.8	71
448	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. **2018**, 13, 37		39
447	Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. **2018**, 123, 952-965		9
446	Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist. **2018**, 37, 302-314		
445	Comparison Between Cu-PSMA-617 PET/CT and F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. **2018**, 16, 385-391		27
444	Prospective comparison of Ga-PSMA PET/CT, F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1884-1897	8.8	53
443	Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. **2018**, 45, 503-524		19
442	Clinical Evaluation of Ga-PSMA-II and Ga-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm. **2018**, 211, 655-660		19
441	Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA . *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 11-19	8.8	67
440	Ga-PSMA-PET/CT in comparison with F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. **2019**, 29, 1221-1230		44
439	Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. **2019**, 60, 227-233		36
438	The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations. **2019**, 7,		4
437	Preliminary results of a Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making. **2019**, 79, 1514-1522		12
436	Current Practical Guidelines for the Most Common Nuclear Medicine Procedures. **2019**, 1099-1138		

435	Salvage lymph node dissection in hormone-naïve men: How effective is surgery?. **2019**, 37, 812.e17-812.e24		4
434	F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. **2019**, 20, 1286-1294		209
433	PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome. **2019**, 9, 93		12
432	Diagnostic Accuracy of Multiparametric MRI versus Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer. **2019**, 293, 350-358		41
431	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. **2019**, 25, 7448-7454		95
430	An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care. **2019**, 9, 1597-1610		18
429	Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. **2019**, 33, 945-954		11
428	Ga-PSMA PET/CT for monitoring response to Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 1054-1062	8.8	33
427	Clinical Outcomes of Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. **2019**, 60, 955-962		57
426	Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study. **2019**, 92, 20190286		22
425	Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2638-2655	8.8	100
424	Current Status of Radionuclide Renal Cortical Imaging in Pyelonephritis. **2019**, 47, 309-312		9
423	Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. **2019**, 16, 157-166		7
422	TEP-PSMA. **2019**, 43, 287-294		
421	HBED-NN: A Bifunctional Chelator for Constructing Radiopharmaceuticals. **2019**, 84, 7501-7508		5
420	Dual-time-point Cu-PSMA-617-PET/CT in patients suffering from prostate cancer. **2019**, 62, 523-532		15
419	Clinical Impact of Lower-Limb Imaging in Ga-PSMA PET/CT for Patients with Prostate Cancer. **2019**, 47, 233-237		6
418	An Introduction to Newer PET Diagnostic Agents and Related Therapeutic Radiopharmaceuticals. **2019**, 47, 203-209		6

417	Molecular Imaging for Primary Staging of Prostate Cancer. **2019**, 49, 271-279		4
416	Prospective comparison of whole-body MRI and Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 1542-1550	8.8	32
415	Effect of External Cooling on Lu-PSMA Uptake by the Parotid Glands. **2019**, 60, 1388-1393		17
414	Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. **2019**, 11,		20
413	Molecular Imaging of Recurrent and Metastatic Prostate Cancer. **2019**, 49, 280-293		5
412	Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. **2019**, 5, 856-863		273
411	New Targets for PET Molecular Imaging of Prostate Cancer. **2019**, 49, 326-336		10
410	Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature. **2019**, 60, 1394-1398		18
409	Fine-tuning of the automated [F]PSMA-1007 radiosynthesis. **2019**, 62, 252-258		4
408	Diagnostic efficacy of PET/CT in bone tumors. **2019**, 17, 4271-4276		1
407	Novel Structured Reporting Systems for Theranostic Radiotracers. **2019**, 60, 577-584		13
406	HTA in nuclear medicine: [68Ga]PSMA PET/CT for patients with prostate cancer. **2019**, 7, 7-20		2
405	Imagerie du cancer de la prostate oligom□astatique, le point de vue du m□decin nucl□aire. **2019**, 43, 227-235		1
404	Evidence-based indications for the planning of PET or PET/CT capacities are needed. **2019**, 7, 65-81		9
403	Synthesis and Applications of Synthetic Peptides. **2019**,		2
402	PSMA-PET/CT imaging in prostate cancer: why and when. **2019**, 7, 377-379		6
401	Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma. **2019**, 9, 1134		16
400	Evaluation of Protic Ionic Liquids Based on Triethanolammonium and Tris(hydroxymethyl)methylammonium Salts as Buffers for 68Ga-Radiolabelling of PSMA-HBED-CC. **2019**, 4, 12524-12527		8

399	Differences in edge artifacts between 68Ga- and 18F-PET images reconstructed using point spread function correction. **2019**, 40, 1166-1173		
398	A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT. **2019**, 44, e566-e573		52
397	Incidental Finding of Acute Lymphocytic Leukemia in a Prostate-Specific Membrane Antigen PET/CT. **2019**, 44, e529-e531		1
396	Is it time to fund routine NHS usage of PSMA PET-CT?. **2019**, 40, 975-979		4
395	Modification of an Anion-Exchange Procedure for 68Ga Preconcentration and Automated Synthesis of [68Ga]Ga-PSMA-11. **2019**, 61, 748-753		0
394	Assessment of 68Ga-PSMA-11 PET positivity predictive factors in prostate cancer. **2019**, 38, 22-28		1
393	Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread. **2019**, 39, 186-212		31
392	Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 901-907	8.8	25
391	Diagnostic performance of Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 908-920	8.8	22
390	Assessment of Ga-PSMA-11 PET positivity predictive factors in prostate cancer. **2019**, 38, 22-28		1
389	Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 31-39	8.8	55
388	Impact of Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. **2019**, 60, 963-970		25
387	68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. **2019**, 79, 454-461		8
386	Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 889-900	8.8	35
385	State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. **2019**, 26, 18-30		12
384	Total-Body Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. **2020**, 61, 405-411		17
383	Head-to-Head Comparison of Ga-PSMA-11 with F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. **2020**, 61, 527-532		64
382	Comparison of 3 Interpretation Criteria for Ga-PSMA11 PET Based on Inter- and Intrareader Agreement. **2020**, 61, 533-539		22

381	[F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 185-191	8.8	9
380	Dynamic patterns of [Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 160-167	8.8	12
379	Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of Ga-PSMA-11 in Patients with Prostate Cancer. **2020**, 61, 716-722		10
378	[Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence. **2020**, 22, 752-763		8
377	Can the Injected Dose Be Reduced in Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. **2020**, 61, 189-193		10
376	An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application. **2020**, 61, 202-209		12
375	Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 147-159	8.8	18
374	Whole-Body Integrated [Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference. **2020**, 22, 788-796		24
373	Prediction nomogram for Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 136-146	8.8	38
372	Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 624-631	8.8	16
371	Challenges in Computer Assisted Interventions. **2020**, 979-1012		3
370	Repeatability of Quantitative F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. **2020**, 61, 1320-1325		10
369	Therapy Response Imaging in Oncology. **2020**,		
368	The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 642-651	8.8	14
367	Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 665-673	8.8	23
366	Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. **2020**, 10, 1678-1693		19
365	Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, F-rhPSMA-7, in Patients with Prostate Cancer. **2020**, 61, 702-709		21
364	Quantitative Test-Retest Measurement of Ga-PSMA-HBED-CC in Tumor and Normal Tissue. **2020**, 61, 1145-1152		13

363	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. **2020**, 61, 1037-1042	5
362	Incidental Detection of Pleomorphic Sarcoma on 68Ga-PSMA PET/CT in a Patient With Prostate Cancer. **2020**, 45, e120-e121	0
361	Digital versus analogue PET in [Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 614-623	8.8 23
360	Detection of Unusual Peritoneal Metastases of Prostate Cancer With 68Ga-Prostate-Specific Membrane Antigen PET/CT. **2020**, 45, 63-64	4
359	Dual-Time Point [Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer. **2020**, 12,	6
358	FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer. **2020**, 8, 2324709620941313	2
357	A Prospective Comparison of F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer	13
356	Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. **2020**, 8,	3
355	The value of F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer. **2020**, 10, 138	7
354	Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology. **2020**, 56,	4
353	Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer. **2020**, 30, 641-648	2
352	Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer. **2020**, 45, 4202-4213	1
351	PSMA PET/CT in primary prostate cancer diagnostics: an overview of the literature. **2020**, 10, 101-108	1
350	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. **2020**,	4
349	Production of [Ga]Ga-PSMA: Comparing a manual kit-based method with a module-based automated synthesis approach. **2020**, 63, 553-563	2
348	Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. **2020**, 20, 723	11
347	Skull vault hemangioma mimicking neoplastic lesion on [Ga]Ga-PSMA-11 PET/CT in a patient with glioblastoma: A case report. **2020**, 15, 2598-2601	1
346	68Ga-PSMA PET/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination?. **2020**, 45, e213-e214	2

345	Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. **2020**, 196, 1006-1017		3
344	Impact of Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. **2020**, 61, 1793-1799		40
343	Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with Ga-PSMA-11-PET. **2020**, 10, 6082-6094		24
342	Nuclear medicine and molecular imaging advances in the 21st century. **2020**, 93, 20200095		12
341	A Prospective Trial of Ga-PSMA and F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. **2020**, 26, 4551-4558		23
340	Impact of PSMA PET/CT in prostate cancer patients clinical management: a pictorial essay of interesting cases with histologic confirmation. **2020**, 8, 207-226		1
339	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [Ga]PSMA-PET-guided metastasis-directed therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2328-2338	8.8	10
338	Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?. **2020**, 214, 1248-1258		11
337	Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations. **2020**, 2, e190037		1
336	Treatment outcomes of metastasis-directed treatment using Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). **2020**, 196, 1034-1043		17
335	Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer. **2020**, 22, 9-14		3
334	Ga-PSMA-11 dose reduction for dedicated pelvic imaging with simultaneous PET/MR using TOF BSREM reconstructions. **2020**, 30, 3188-3197		3
333	Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer. **2020**, 10, 2705		10
332	Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients' disease management and adequacy of impact. **2020**, 10, 2104		14
331	DNA Damage in Blood Leukocytes of Prostate Cancer Patients Undergoing PET/CT Examinations with [Ga]Ga-PSMA I&T. **2020**, 12,		7
330	Intraoperative Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study. **2020**, 61, 1500-1506		16
329	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. **2020**, 148, 102861		10
328	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. **2020**, 38, 1963-1996		51

327	Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 1852-1863	8.8	12
326	Impact of Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. **2020**, 61, 1153-1160		37
325	R□idive testiculaire isol□ d□un ad□nocarcinome prostatique r□v□l□ par TEP/TDM 18F-fluorocholine. **2020**, 44, 76-78		
324	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. **2020**, 20, 362		13
323	PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis. **2020**, 196, 637-646		4
322	Lesion Detection and Administered Activity. **2020**, 61, 1406-1410		3
321	Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2804-2815	8.8	12
320	Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 123-133	8.8	5
319	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 469-476	8.8	42
318	PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 493-500	8.8	3
317	The role of Gallium-prostate-specific membrane antigen positron emission tomography on staging of high-risk localized prostate cancer: for all high-risk patients or would it be better to select them?. **2021**, 9, 54-59		
316	Novel PET imaging methods for prostate cancer. **2021**, 39, 687-699		2
315	Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue. **2021**, 31, 2199-2208		0
314	Improved oncological outcome after radical prostatectomy in patients staged with Ga-PSMA-11 PET: a single-center retrospective cohort comparison. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1219-1228	8.8	3
313	Safety, Biodistribution, and Radiation Dosimetry of F-rhPSMA-7.3 in Healthy Adult Volunteers. **2021** , 62, 679-684		7
312	Artificial intelligence-based detection of lymph node metastases by PET/CT predicts prostate cancer-specific survival. **2021**, 41, 62-67		11
311	FAPI PET/CT: Will It End the Hegemony of F-FDG in Oncology?. **2021**, 62, 296-302		29
310	Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer. **2021**, 9, 107-112		1

309	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [Ga]Ga-PSMA ligand PET/CT(MRI). **2021**, 24, 439-447		
308	Renal Cortical Ga-PSMA-11 PET and Tc-DMSA Images. **2021**, 49, 30-33		4
307	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. **2021**, 62, 675-678		4
306	The Impact of Monosodium Glutamate on Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. **2021**, 62, 1244-1251		3
305	Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. **2021**, 62, 1235-1241		7
304	Comparison of Multiparametric Magnetic Resonance Imaging and Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Detecting Carcinoma Prostate in Patients with Serum Prostate-Specific Antigen between 4 and 20 ng/ml. **2021**, 36, 245-251		
303	The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer. **2021**, 23, 1-2		6
302	Radiopharmaceuticals in Clinical Diagnosis and Therapy. **2021**, 103-118		1
301	The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. **2021**, 11, 3		8
300	Head-to-Head Comparison of Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. **2021**, 62, 1258-1263		4
299	Patient preparation for PET studies. **2021**,		
298	Head-to-Head Comparison of Ga-NOTA (Ga-NGUL) and Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study. **2021**, 62, 1457-1460		2
297	Predictive factors of tumor sink effect: Insights from Lu-Prostate-specific membrane antigen therapy. **2021**, 35, 529-539		0
296	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1626-1638	8.8	50
295	Combination of Forced Diuresis with Additional Late Imaging in Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. **2021**, 62, 1252-1257		6
294	Diagnostic value of F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative Ga-PSMA PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2970-2977	8.8	5
293	Urachal remnant metastasis detected on [Ga] PSMA-11 PET/CT in an asymptomatic prostate cancer patient with biochemical recurrence. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 3003-3004	8.8	1
292	Evaluation of [Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision. **2021**, 11, 21		0

291	An HPLC and UHPLC-HRMS approach to study PSMA-11 instability in aqueous solution. **2021**, 6, 14		2
290	PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. **2021**, 62, 1545-1549		8
289	Prospective comparison of F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2951-2959	8.8	7
288	The use of systematic review evidence to support the development of guidelines for positron emission tomography: a cross-sectional survey. **2021**, 31, 6992-7002		
287	Comparison of Regularized Reconstruction and Ordered Subset Expectation Maximization Reconstruction in the Diagnostics of Prostate Cancer Using Digital Time-of-Flight Ga-PSMA-11 PET/CT Imaging. **2021**, 11,		2
286	The Role of [F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [C]Choline PET/CT and Histopathological Analysis. **2021**, 13,		0
285	Dynamic Contrast-Enhanced MRI of Prostate Lesions of Simultaneous [Ga]Ga-PSMA-11 PET/MRI: Comparison between Intraprostatic Lesions and Correlation between Perfusion Parameters. **2021**, 13,		2
284	Restaging the Biochemical Recurrence of Prostate Cancer with [Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management. **2021**, 13,		2
283	Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for Ga-PSMA-11 PET/CT. **2021**, 62, 1550-1557		1
282	Impact of total variation regularized expectation maximization reconstruction on the image quality of Ga-PSMA PET: a phantom and patient study. **2021**, 94, 20201356		3
281	Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer. **2021**, 18, 5-10		0
280	Preclinical Assessment Addressing Intravenous Administration of a [Ga]Ga-PSMA-617 Microemulsion: Acute In Vivo Toxicity, Tolerability, PET Imaging, and Biodistribution. **2021**, 26,		2
279	Nuklearmedizinische Diagnostik und Therapie des Prostatakarzinoms. **2021**, 28, 58-72		
278	Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer. **2021**, 11, 664225		1
277	The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using Ga-PSMA PET/CT as References. **2021**, 11, 658669		1
276	Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with Ga and Lu as Potential Theranostic Agent for Colon Cancer. **2021**, 13,		0
275	Nuclear medicine and molecular imaging in clinical practice: yesterday, today and tomorrow. **2021**, 93, 357-362		1
274	Combining Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. **2021**, 11, 640467		0

273	Competition ('Steal' Phenomenon) between [Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue. **2021**, 13,		1
272	Prostate-specific Membrane Antigen PET in Prostate Cancer. **2021**, 299, 248-260		9
271	Efficacy and Safety of [Ac]Ac-PSMA-617 Augmented [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. **2021**, 13,		8
270	Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. **2021**, 16, 2909-2941		13
269	Cases of thyroid cartilage metastasis as abnormal findings seen in prostate cancer patients visualized by 68Ga-PSMA-11 PET/CT. **2021**, 52,		
268	Tumor sink effect in Ga-PSMA-11 PET: Myth or Reality?. **2021**,		2
267	68Ga-PSMA-I&T-PET/CT interobserver and intraobserver agreement for prostate cancer: a lesion based and subregional comparison study among observers with different levels of experience. **2021**, 42, 1122-1129		0
266	Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival. **2021**, 42, 1217-1226		1
265	Ultrafast Photoclick Reaction for Selective F-Positron Emission Tomography Tracer Synthesis in Flow. **2021**, 143, 10041-10047		9
264	[F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue. **2021**, 14,		1
263	ASSESSMENT OF PATIENT'S RADIATION EXPOSURES RESULTED FROM PET/CT 18F-FCH AND 68GA-PSMA PROCEDURES. **2021**, 195, 349-354		
262	Non-invasive molecular imaging of kidney diseases. **2021**, 17, 688-703		4
261	Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT. **2021**, 11,		1
260	Clinical insignificance of [F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 4495-4507	8.8	9
259	Give to Fryback what is Fryback's, and to new PET technologies what is new PET technologies'. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2676-2677	8.8	0
258	PET/CT Imaging of Prostate Cancer. Modern Versions of Radiopharmaceuticals. **2021**, 4, 23-36		
257	Assessment of occupational exposure from shielded and unshielded syringes for clinically relevant positron emission tomography (PET) isotopes-a Monte Carlo approach using EGSnrc. **2021**, 41,		0
256	Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 4456-4462	8.8	3

255	The value of intravenous contrast medium in PSMA PET/CT imaging in patients with biochemical recurrence of prostate cancer. **2021**, 42, 1239-1246		
254	[Ga]Ga-PSMA-11: The First FDA-Approved Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. **2021**, 14,		10
253	TEP/TDM aux ligands du PSMA dans le cancer de la prostate : quoi de neuf en 2021 ?. **2021**, 45, 252-256		
252	Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with Ga-PSMA-11 PET/CT. **2021**, 49, 235-240		1
251	Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a Phantom study. **2021**,		0
250	[F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	1
249	Diagnostic performance and clinical impact of Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study). **2021**,		1
248	Whole-body uptake classification and prostate cancer staging in Ga-PSMA-11 PET/CT using dual-tracer learning. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	3
247	Comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer: a protocol for systematic review and meta-analysis. **2021**, 52,		
246	Renal Cortical Scarring: Ga-PSMA-11 PET versus Tc-DMSA Scan in a Case with Pyelonephritis. **2021**,		2
245	A comprehensive assessment of Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. **2021**,		2
244	The added value of PSMA PET/MR radiomics for prostate cancer staging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	5
243	Prostate Cancer Theranostics: From Target Description to Imaging. **2021**, 16, 383-390		
242	Response Assessment and Prediction of Progression-Free Survival by Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing Lu-PSMA-617 Radioligand Therapy. **2021**, 11,		2
241	Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer. **2021**, 11, 715020		0
240	Standardisation of conventional and advanced iterative reconstruction methods for Gallium-68 multi-centre PET-CT trials. **2021**, 8, 52		0
239	Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. **2021**, 10, 3130-3143		2
238	Myelofibrosis Pattern in 68Ga-PSMA PET/CT of a Patient With Recurrence Prostate Cancer. **2021**, 47,		0

237	Biphasic GA 68-labeled prostate specific membrane antigen-11 positron emission tomography/computed tomography scans in the differential diagnosis and risk stratification of initial primary prostate cancer. **2021**, 11, 3619-3628		0
236	What's behind Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 4042-4053	8.8	11
235	What to Trust, PSA or [Ga]Ga-PSMA-11: Learn from Experience. **2021**, 13, 597-601		
234	PSMA Theranostics: Science and Practice. **2021**, 13,		6
233	Clinical Applications of PET/MR Imaging. **2021**, 59, 853-874		1
232	Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study. **2021**, 1		4
231	PET Imaging for Prostate Cancer. **2021**, 59, 801-811		6
230	F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval. **2021**,		3
229	Interreader agreement in evaluation of 68Ga-PSMA PET/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups. **2022**, 43, 86-91		0
228	Head-to-head comparison of [´Ga]Ga-P16-093 and [´Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	1
227	Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. **2021**, 7, 1635-1642		20
226	Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. **2021**, 385, 1091-1103		202
225	Theranostics in oncology: What radiologists want to know. **2021**, 142, 109875		1
224	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. **2021**,		7
223	Prostate cancer: Molecular imaging and MRI. **2021**, 143, 109893		1
222	Comparison of Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis. **2021**, 33, 61-71		1
221	Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?. **2021**, 47, 1243-1249		0
220	Nuclear Medicine Imaging Procedures in Oncology. **2021**, 2294, 297-323		0

219	Molecular imaging and biochemical response assessment after a single cycle of [Ac]Ac-PSMA-617/[Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [Lu]Lu-PSMA-617 monotherapy. **2021**, 11, 4050-4060		16
218	Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging-utilization of a short-pass filter to reduce technical pitfalls. **2021**, 10, 3972-3985		1
217	The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. **2021**, 27, 2928-2937		17
216	Establishment and prospective validation of an SUV cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by Ga-PSMA PET/CT: a real-world study. **2021**, 11, 8396-8411		4
215	Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal F-fluorocholine PET/CT: 1084 examinations. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2935-2950	8.8	5
214	Whole-body magnetic resonance imaging for prostate cancer assessment: Current status and future directions. **2020**,		6
213	Molecular and Functional Imaging in Oncology Therapy Response. **2020**, 255-272		1
212	PET/CT and PET/MRI, Normal Variations, and Artifacts. **2020**, 549-584		1
211	F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2031-2037	8.8	5
210	68Ga-PSMA PET/CT With Incidental Finding of COVID-19 in an Asymptomatic Patient. **2020**, 45, 1032-1033		4
209	Evaluation of SUV normalized by lean body mass (SUL) in Ga-PSMA11 PET/CT: a bi-centric analysis. **2019**, 9, 103		7
208	Added value of Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous Tc bone scintigraphy. **2020**, 10, 31		10
207	[Tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. **2020**, 10, 45		14
206	Neuron-specific enolase has potential value as a biomarker for [F]FDG/[Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. **2020**, 10, 52		8
205	Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT. **2020**, 10, 108		4
204	Day-to-day variability of [Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation. **2020**, 10, 132		5
203	Preclinical comparison of four [F, Ga]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics. **2020**, 10, 149		15
202	Optimization of PET protocol and interrater reliability of F-PSMA-11 imaging of prostate cancer. **2020**, 10, 14		8

201	Kinetic modeling of Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients. **2020**, 10, 12		5
200	Pre-test Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy-validation of a prediction model. **2020**, 10, 6		4
199	Performance evaluation of Cerenkov luminescence imaging: a comparison of Ga with F. **2019**, 6, 17		10
198	Optimization of injected Ga-PSMA activity based on list-mode phantom data and clinical validation. **2020**, 7, 20		1
197	Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality. **2020**, 7, 54		2
196	Non-FDG PET/CT in Diagnostic Oncology: a pictorial review. **2019**, 3, 20		6
195	Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer. **2017**, 8, 66112-66116		13
194	68GA-PSMA LABELED BIOMARKER FOR POSITRON EMISSION TOMOGRAPHY (LITERATURE REVIEW). **2018**, 5, 46-52		1
193	PET imaging in adaptive radiotherapy of prostate tumors. **2018**, 62, 404-410		4
192	First Experiences with Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients. **2021**, 62, 975-978		4
191	Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma?. **2018**, 33, 202-208		4
190	Nonspecific Uptake of Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature. **2018**, 33, 317-325		21
189	Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml. **2019**, 35, 202-207		6
188	Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA		9
187	Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop. **2018**, 17, 261-269		9
186	[Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [Lu]Lu-PSMA-617 treatment. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	1
185	Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	1
184	PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. **2021**,		4

183	PSMA-Based Therapy of Metastasized Castrate-Resistant Prostate Cancer. **2018**, 451-464		
182	False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography. **2018**, 17, 305-307		1
181	Molecular Guidance for Planning External Beam Radiation Therapy. **2019**, 977-1006		3
180	Définition du workflow clinique et du protocole TEP/IRM PSMA pour l'évaluation du cancer de la prostate : expérience initiale et résultats. **2019**, 203, 662-669		
179	99MTc-PSMA radionuclide imaging of prostate cancer: an innovative diagnostic direction in nuclear medicine. **2020**, 26-38		
178	68Ga-PSMA-Avid Small Cell Lung Cancer on PET/CT: Incidental Second Malignancy in Treated Prostate Cancer. **2020**, 45, 1016-1017		1
177	Initial Experience of Clinical Use of [Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study. **2021**, 14,		1
176	F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer. **2021**, 11, 759053		1
175	Ga-EMP-100 PET/CT-a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma-first in-human biodistribution and imaging results. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	1
174	Early molecular imaging response assessment based on determination of total viable tumor burden in [Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [Lu]Lu-PSMA-617 radioligand therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	2
173	Hot needles can confirm accurate lesion sampling intraoperatively using [F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	3
172	Proactive Response of Nuclear Medicine Department in Current Coronavirus Disease-19 Pandemic. **2020**, 35, 278-280		
171	Incremental Value of Post Diuretic 68Ga-PSMA-11 PET-CT in Characterization of Indeterminate lLesions in Prostate Cancer. **2020**, 21, 3719-3723		0
170	Labeling with Gallium-68. **2020**, 291-323		1
169	Selection and Validation of an SUV max Cutoff Value to Discriminate Prostate Cancer From Benign Prostate Hypertrophy by 68Ga-PSMA PET/CT: A Real-World Study.		
168	N-stage Challenges. **2020**, 275-292		
167	[Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. **2020**, 10, 135		3
166	Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. **2018**, 8, 351-359		9

165	Synthesis and assessment of ZD2-(Ga-NOTA) specific to extradomain B fibronectin in tumor microenvironment for PET imaging of pancreatic cancer. **2019**, 9, 216-229		3
164	Direct comparison of Tc-PSMA SPECT/CT and Ga-PSMA PET/CT in patients with prostate cancer. **2020**, 8, 1-7		4
163	[Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. **2020**, 10, 349-374		7
162	Lung uptake detected by Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2: a case series. **2021**, 11, 300-306		1
161	The Impact of 18F-DCFPyL PSMA PET-CT in the Management of Prostate Cancer Biochemical Recurrence. **2021**, 11, 393-403		
160	Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and Ga-PSMA-PET/MRI - What is the value of quantitative data from multiparametric MRI alone or in conjunction with clinical information?. **2021**, 146, 110044		1
159	Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. **2021**, 15, 101293		0
158	Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities. **2021**, 60, 417-424		
157	The relationship between 68Ga-PSMA uptake and Gleason Score and PSA levels in patients with prostate cancer. **2021**, 3, 327-332		
156	Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management. **2021**, 11, 758958		2
155	Preclinical assessment of [68Ga]Ga-Cell Death Indicator (CDI): a novel hsp90 ligand for positron emission tomography of cell death. **2021**,		0
154	Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET/CT PET/MRI. **2021**, 20210728		1
153	Radioguided surgery for intraoperative detection of occult lesions. **2021**,		
152	The Added Value of F-FDG PET/CT Compared with Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.. **2022**, 63, 69-75		2
151	Diagnostic Reference Levels for nuclear medicine imaging in Austria: A nationwide survey of used dose levels for adult patients.. **2022**,		0
150	Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by Ga-PSMA PET/CT.. **2022**, 12,		1
149	[18F]DCFPyL PET/CT for Imaging of Prostate Cancer.. **2022**,		2
148	[´Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	0

147	Utility of F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.. **2022**,		3
146	Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy.. **2022**, 12,		
145	Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer.. **2021**, 9, 811972		
144	Preclinical biodistribution and dosimetry and human biodistribution comparing F-rhPSMA-7 and single isomer F-rhPSMA-7.3.. **2022**, 12, 8		0
143	[Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?]. **2022**, 1		
142	Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.. **2021**,		5
141	Molecular Guidance for Planning External Beam Radiation Therapy in Oncology. **2022**, 1-40		
140	Evaluation of hybrid PET/CT imaging with the 68Ga-labelled PSMA ligand in patients with prostate cancer and biochemical progression in the low-range values of PSA after radical prostatectomy. **2022**, 54, 29		
139	PET imaging of prostate cancer. **2022**,		
138	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer.. **2022**, 14,		2
137	Application of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer Clinical Relapse.. **2022**,		0
136	Normal Variants, Pitfalls, and Artifacts in Ga-68 Prostate Specific Membrane Antigen (PSMA) PET/CT Imaging. **2022**, 2,		0
135	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with F-DCFPyL.. **2022**, 2022, 7056983		0
134	Safety and Diagnostic Yield of Ga Prostate-specific Membrane Antigen PET/CT Guided Robotic-assisted Transgluteal Prostatic Biopsy.. **2022**, 204066		2
133	Event-free survival after ´Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	3
132	Utilidad de los radioligandos PSMA en el diagn□stico y tratamiento del carcinoma de pr□tata. **2022**, 41, 126-135		0
131	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC.. **2022**, 14,		1
130	Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography: A Practical Guide for Radiologists and Clinicians.. **2022**, 14, e22917		

129	Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions.. **2022**, 63, 514-521		1
128	Total-body PET/CT - first clinical experiences and future perspectives.. **2022**,		0
127	The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma.. **2022**,		0
126	Radiotherapy in oligometastatic prostate cancer-a´pattern of care survey among members of the German Society for Radiation Oncology (DEGRO).. **2022**, 1		0
125	Time point-independent tumor positivity of Ga-PSMA-PET/CT pre- and post-biopsy in high-risk prostate cancer.. **2022**, 1		
124	Determination of optimal ´Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	6
123	ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. **2021**, 21, 1-212		6
122	Radiation Protection and Occupational Exposure on [Ga]Ga-PSMA-11 based Cerenkov Luminescence Imaging Procedures in robot assisted Prostatectomy.. **2021**,		0
121	Clinical Trial Protocol for PSMA-SELECT: A Dutch National Randomised Study of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as a Triage Tool for Pelvic Lymph Node Dissection in Patients Undergoing Radical Prostatectomy.. **2021**,		0
120	18F-FDG and Non-FDG PET Radiopharmaceuticals. **2022**, 27-31		
119	Radiolabeled PSMA Inhibitors.. **2021**, 13,		2
118	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	1
117	The differential diagnostic value of dual-phase F-DCFPyL PET/CT in prostate carcinoma.. **2022**,		0
116	Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	2
115	The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA . **2022**, 61, 120-129		0
114	Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients.. **2022**, 13, 75		1
113	Joint EANM, SNMMI and IAEA Enabling Guide: How to Set Up a Theranostics Centre.. **2022**,		0
112	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. **2022**, 1-55		

111	All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others.. **2022**, 5, 283-283		0
110	An Explorative Study of the Incidental High Renal Excretion of [F]PSMA-1007 for Prostate Cancer PET/CT Imaging.. **2022**, 14,		
109	Prostate cancer cardiac metastasis detected on serial imaging with [Ga] PSMA-11 PET/CT.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	0
108	Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends. **2022**, 11, 2738		0
107	Inter-Observer Variability in the Interpretation of ⁶⁸Ga-PSMA PET-CT Scan according to PROMISE Criteria. **2022**, 12, 1-13		
106	Predictors of Bone Metastases at 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence. **2022**, 12, 1309		0
105	Molecular Guidance for Planning External Beam Radiation Therapy in Oncology. **2022**, 1-40		
104	Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent: Impact of Delayed Imaging. **2022**, 11, 3311		0
103	Development and validation of a nomogram for predicting the likelihood of metastasis in prostate cancer patients undergoing Ga-68 PSMA PET/CT due to biochemical recurrence. Publish Ahead of Print,		
102	EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA). *European Journal of Nuclear Medicine and Molecular Imaging*,	8.8	
101	Effect of hormonal therapy on 18F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen. **2022**,		0
100	Mapping of local recurrences after radical prostatectomy using 68-Gallium-PSMA-PET/CT: Implications for post-prostatectomy radiotherapy clinical target volumes. **2022**,		
99	Fibroblast Activation Protein Inhibitor Theranostics. **2022**, 17, 453-464		0
98	Novel Positron-Emitting Radiopharmaceuticals. **2022**, 1-48		
97	Radiomics in prostate cancer: an up-to-date review. **2022**, 14, 175628722211090		9
96	Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy. *European Journal of Nuclear Medicine and Molecular Imaging*,	8.8	0
95	EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. **2022**,		1
94	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. *European Journal of Nuclear Medicine and Molecular Imaging*,	8.8	1

93	The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on 68Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients. jnumed.122.264101	0
92	Assessment and Registration of Effective Doses Used in Diagnostic Nuclear Medicine Examinations. **2022**, 94, 64-75	
91	Prostate Cancer. **2023**, 370-393	
90	COMPARISON OF THREE DIFFERENT METHODS IN [68 Ga]Ga-PSMA11 RADIOLABELING.	0
89	Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study. **2022**, 12,	0
88	A 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS. jnumed.122.264298	
87	The value of 68Ga-PSMA-11 PET/CT in patients with prostate cancer and inconclusive standard imaging at primary staging. Publish Ahead of Print,	
86	Personal dosimetry for positron emitters, and occupational exposures from clinical use of gallium-68.	0
85	The 18F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer. 12,	
84	Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction with 18F-PSMA-1007 PET: comparison among different volume segmentation thresholds.	3
83	A pilot study of 68´Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma. **2022**, 12,	0
82	The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy□ multicenter retrospective analysis.	0
81	[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates.	2
80	Molecular Guidance for Planning External Beam Radiation Therapy in Oncology. **2022**, 1687-1726	0
79	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. **2022**, 1-55	0
78	Radionuclide Therapy in Prostate Cancer. **2022**, 273-299	0
77	Novel Positron-Emitting Radiopharmaceuticals. **2022**, 169-216	0
76	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. **2022**, 1023-1075	0

75	Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer. **2022**,	0
74	Various Aspects of Fasting on the Biodistribution of Radiopharmaceuticals. **2022**, 23,	0
73	Combined [68´Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.	1
72	Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study. jnumed.122.263889	1
71	Artificial Intelligence in Oncological Hybrid Imaging.	0
70	PSMA-directed imaging and therapy of salivary gland tumors: a single-center retrospective study. jnumed.122.264342	2
69	Positron Range Corrections and Denoising Techniques for Gallium-68 PET Imaging: A Literature Review. **2022**, 12, 2335	0
68	Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial. **2022**,	0
67	Development and validation of a UV-Radio-HPLC method to assess chemical and radiochemical purity of [68Ga] Ga-PSMA-11. **2022**, 190, 110487	0
66	The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer.	0
65	[99mTc]Tc-PSMA-T4: Novel SPECT Tracer for Metastatic PCa: From Bench to Clinic. **2022**, 27, 7216	0
64	COMP Report: CPQR technical quality control guidelines for use of positron emission tomography/computed tomography in radiation treatment planning.	0
63	The impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence.	2
62	PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. **2022**, 12, 2594	1
61	Evaluation of [68´Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria. **2022**, 12,	1
60	Letter to the editor: Combined [68´Ga]Ga-PSMA-11 and low-dose [18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.	0
59	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 guideline. **2022**,	0
58	Radiation Safety Considerations During Radiopharmaceutical Preparation. **2022**, 129-152	0

57	Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET/CT for risk stratification in newly diagnosed prostate cancer. 12,	0
56	Altered Glucose Metabolism Postchemotherapy Precedes PSMA Expression in Poorly Differentiated Prostate Cancer. Publish Ahead of Print,	0
55	A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. **2022**, 14, 5461	1
54	F18-PSMA Cerenkov luminescence and flexible autoradiography Imaging in a prostate cancer mouse model and first results of a radical prostatectomy feasibility study in men. jnumed.122.264670	0
53	Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage.	0
52	Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams.	0
51	PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study. **2022**, 14, 5680	0
50	Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.	0
49	Comparing digital to analog prostate-specific membrane antigen-targeted piflufolastat 18F PET/CT in prostate cancer patients in early biochemical failure. Publish Ahead of Print,	0
48	18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer. 12,	0
47	Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy. 12,	0
46	Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy.	0
45	Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study. jnumed.122.264964	0
44	Radiopharmaceuticals and contrast agents. **2023**, 35-67	0
43	PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.	2
42	Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy.	0
41	Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions. **2023**, 15, 473	0
40	Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?. **2023**, 15, 323	0

39	A novel figure of merit to investigate 68Ga PET/CT image quality based on patient weight and lesion size using Q.Clear reconstruction algorithm: A phantom study. **2023**, 106, 102523	0
38	18 F-PSMA-1007PET/CT in patients with biochemical recurrence after radical prostatectomy: Diagnostic performance and impact on treatment management. **2023**, 5, 100021	0
37	The clinical application of 68Ga-PSMA PET/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer. **2023**, 28, 101616	0
36	The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence. **2023**, 15, 247	0
35	High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data. Publish Ahead of Print,	0
34	Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response.	0
33	Is there more than meets the eye in PSMA imaging in prostate cancer with PET/MRI? Looking closer at uptake time, correlation with PSA and Gleason Score.	0
32	In vitro and in vivo comparative study of 68Ga-labeled DOTA-, NOTA-, and HBEDCC-chelated radiotracers targeting prostate-specific membrane antigen.	0
31	Head-to-Head Comparison of 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer. Publish Ahead of Print,	0
30	Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model. 13,	0
29	Automatic segmentation of prostate cancer metastases in PSMA PET/CT images using deep neural networks with weighted batch-wise dice loss. **2023**, 158, 106882	0
28	Mask R-CNN assisted 2.5D object detection pipeline of 68Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging. **2023**, 13,	0
27	Superscan-Like Pattern on 18F-Choline PET/CT in a Patient With Essential Thrombocythemia. Publish Ahead of Print,	0
26	An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients. jnumed.122.265159	0
25	Combination of [68Ga]Ga-PSMA PET/CT and [18F]FDG PET/CT in demonstrating dedifferentiation in castration-resistant prostate cancer. **2023**,	0
24	Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge. 13,	1
23	Digital PET for recurrent prostate cancer: how the technology help.	0
22	Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center Real-World Experience. **2023**, 15, 1376	0

21	18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer.	0
20	Imaging Recommendations for Theranostic PET-CT in Oncology.	0
19	A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies. **2023**, 50, 91-105	0
18	18F-DCFPyL PET/CT guidelines. **2023**,	0
17	Gu del procedimiento de la PET/TC con 18F-DCFPyL. **2023**,	0
16	Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study. **2023**, 33, 3343-3353	0
15	Radionuclide Therapies and Correlative Imaging. **2023**, 838-870	0
14	Introduction to Correlative Imaging. **2023**, 1-29	0
13	Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with 68Ga-PSMA PET/CT Features in Primary Staging. **2023**, 15, 1716	1
12	Optimization of Bayesian penalized likelihood reconstruction for 68Ga-prostate-specific membrane antigen-11 PET/computed tomography. Publish Ahead of Print,	0
11	Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy.	0
10	Role of [68Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer.	0
9	Imaging quality of an artificial intelligence denoising algorithm: validation in 68Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer.	0
8	PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment. **2023**, 15, 2027	0
7	Prediction of pelvic lymph node metastases and PSMA PET positive pelvic lymph nodes with multiparametric MRI and clinical information in primary staging of prostate cancer. **2023**, 10, 100487	0
6	Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography on the Therapeutic Decision of Prostate Carcinoma Primary Staging: A Retrospective Analysis at the Brazilian National Public Health System.	0
5	Diagnostic Impact of Dual-Time PET/CT with 68Gallium-PSMA in Prostate Cancer and 68Gallium-DOTATOC in Neuroendocrine Tumors. **2023**, 11, 1052	0
4	Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. **2023**, 15, 1240	0

3	Is there more than meets the eye in PSMA imaging in prostate cancer with PET/MRI? Looking closer at uptake time, correlation with PSA and Gleason score. **2023**, 7,	0
2	Role of radiomic analysis of [18F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging.	0
1	Detection efficacy of ′[89Zr]Zr-PSMA-617 PET/CT in ′[68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer.	0